Built on over 20 years of research at the British Columbia (BC) Cancer Agency and the University of British Columbia (UBC)—where, in addition to Vita Imaging’s investment of over $5 million, approximately US$15 million was expended to advance the technology by the BCCA Research Centre and a predecessor company—Vita Imaging’s AURA™ platform uses non-invasive Raman spectroscopy to help clinicians evaluate benign versus malignant skin lesions in under 1.5 seconds. Following 2026 regulatory and quality milestones—including an AMA Category III CPT® tracking code (a temporary emerging-technology data-collection code with no established payment) and ISO 13485 quality certification—AURA™ is advancing toward FDA Class II 510(k) market clearance and international regulatory registrations across Europe, the UK, and the Middle East.
Skin cancer is the most common cancer worldwide, affecting 1 in 5 Americans in their lifetime⁵. When malignant melanoma is caught early, the 5-year survival rate is 99%⁵.
Yet initial triage still relies heavily on subjective naked-eye inspection (ABCDE guidelines), whose effectiveness varies with physician experience. When a lesion appears suspicious, clinicians perform a surgical punch or excisional biopsy—requiring local anesthesia, sutures, potential scarring, and a 1 to 3 week wait for pathology lab confirmation. Because visual inspection alone is limited, millions of benign lesions are surgically excised each year, contributing to $8.1B to $8.9B in annual U.S. skin cancer treatment costs⁵.
“Visual inspection of suspicious skin lesions using the naked eye alone is not enough to ensure the accurate diagnosis of skin cancer.” — University of Birmingham Study (2018)⁶
Vita Imaging developed AURA™ to give clinicians objective optical physics right at the point of care. Using patented Rapid Raman Spectroscopy, AURA™ directs a harmless near-infrared light beam onto a suspicious lesion and measures molecular vibrations within the tissue—capturing a biochemical “molecular fingerprint” in under 1.5 seconds (1.0s scan + 0.5s processing) with minimal skin preparation (a quick alcohol wipe, and trimming if needed for dense hair)¹. For patients who present with dozens of suspicious lesions in a single visit, 1.5-second speed is critical. If a lesion is flagged as suspicious, the physician proceeds to a punch or excisional biopsy sent to a pathologist for definitive diagnosis.
AURA™ is designed to evaluate both deadly Melanoma and Non-Melanoma Skin Cancers (Basal and Squamous Cell Carcinomas)—with Basal and Squamous Cell Carcinomas alone accounting for approximately 90% of all skin cancers¹. Clinicians can operate AURA™ at paired sensitivity and specificity thresholds—95% sensitivity / 68% specificity or 90% sensitivity / 82.1% specificity².
AURA™ is currently seeking FDA Class II 510(k) clearance for use by dermatologists, with the potential—subject to future regulatory clearances—to expand to primary care physicians and physician extenders. The workflow takes three straightforward steps:
Rather than relying on surface-level visual cues, AURA™ applies laser-based Raman spectroscopy to evaluate biochemical tissue changes directly related to malignancy—combining sub-1.5-second lesion scanning, paired clinical sensitivity/specificity performance, and broad coverage across Melanoma, BCC, and SCC in a compact point-of-care console¹˒²:
Early-stage medtech companies often face decades of foundational development before reaching regulatory readiness. With Vita Imaging, in addition to Vita’s investment of over $5 million, approximately US$15 million was expended to advance the technology by the BCCA Research Centre and a predecessor company⁴. Over 2025 and 2026, Vita Imaging achieved major regulatory, clinical, and quality milestones—including the April 24, 2026 FDA Final Order reclassifying optical skin cancer devices to Class II (510(k) pathway), activation of an AMA Category III CPT® tracking code (January 1, 2026), multi-site U.S. VA Hospital and Arizona clinic studies, and ISO 13485 quality certification (June 25, 2026)³˒⁴:
Vita Imaging’s commercial business model is structured around three complementary streams: AURA™ console capital sales (alongside a 60/40 revenue-sharing physician lease option), single-use disposable probe tips required for calibration and patient hygiene, and annual service contracts—plus an anonymized spectral imaging database collected through clinic data-sharing agreements⁷. Simultaneously, our June 2026 ISO 13485 quality certification supports international registration pathways across the EU, UK, UAE, and Saudi Arabia (where health insurance is legally required to cover skin cancer diagnostics)³˒⁸:
Through our exclusive worldwide license with the BC Cancer Agency (BCCA) and UBC, Vita Imaging controls 8 issued patent families covering high-speed Raman spectroscopy for both skin cancer (AURA™) and internal organ cancers (CORE™)⁴. Because the base Raman console remains identical—requiring only a miniature fiber-optic probe inserted into a standard medical endoscope—Vita Imaging plans to explore future expansion into lung, GI, stomach, colorectal, pancreatic, and cervical cancer detection, where human pilot studies have already been published⁴.
A breakthrough medical device requires both seasoned commercial leadership and deep scientific expertise. Complementing our executive team introduced at the top of this page—Former NASDAQ CEO-Founder Thinh Tran (founded Sigma Designs in 1982, scaling it to a $2B peak market cap over 36 years, and personally advanced $2.4M+ to Vita), COO Victoria Reade (25+ years MedTech leadership & prior FDA device approval), and CFO Dzung Wright (30+ years public & high-growth finance)⁹—Vita Imaging is supported by six pioneering biophysicists, academic dermatologists, and clinical researchers from the BC Cancer Agency, UBC, and California Skin Institute who developed the Raman spectroscopy platform and lead our clinical studies²˒⁴:
“We didn’t start Vita Imaging because it was easy—we started it because we knew it was necessary. After seeing firsthand how long and uncertain the path to a cancer diagnosis can be, we set out to give doctors a tool to detect cancer in seconds.” — Thinh Tran, Founder, Chairman & CEO
In medical devices, a major value inflection often occurs as a platform advances from clinical studies toward regulatory clearance and recurring commercial revenue. Investing in Vita Imaging today positions you:
We invite you to join CEO Thinh Tran, Lead Investor Tuoc Luong, and the Vita Imaging team in advancing 1.5-second, non-invasive cancer detection for patients and clinics worldwide. To begin your investment in Vita Imaging today, simply enter your desired investment amount in the floating WeFunder deal panel on the right of this page.
[1] Scan Speed (<1.5 Seconds) & Broad-Spectrum Detection: Vita Imaging Inc. SEC Form C-AR (Annual Report filed July 8, 2026), p. 7 (single 1.5s AURA scan; Non-Melanoma Skin Cancers [BCC & SCC] comprise approximately 90% of all skin cancers); Vita Imaging Investor Presentation (Updated Sept / Rev. Nov 2026), Slides 5–7 & 9 (1.0s probe contact + 0.5s data processing time).
[2] AURA™ Paired Clinical Sensitivity & Specificity: Vita Imaging Investor Presentation (2026), Slides 6 & 9 (paired clinician-selectable operating points: 95% sensitivity / 68% specificity and 90% sensitivity / 82.1% specificity); Zhao J, Zeng H, Kalia S, Lui H. Incorporating patient demographics into Raman spectroscopy algorithm improves in vivo skin cancer diagnostic specificity. Translational Biophotonics. 2019 Dec;1(1-2):e201900016 (published pair: 99.0% sensitivity / 44.5% specificity, cited in SEC Form C-AR, p. 7); Lui H, Zhao J, McLean D, Zeng H. Real-time Raman spectroscopy for in vivo skin cancer diagnosis. Cancer Research. 2012;72(10):2491-2500 (1,000+ lesion clinical study).
[3] 2026 Regulatory, Tracking Code & Quality Milestones: SEC Form C-AR (July 8, 2026), pp. 6, 8–9: (a) U.S. FDA Final Order effective April 24, 2026 reclassifying optical skin cancer diagnostic devices from Class III into Class II (510(k) predicate pathway); (b) AMA CPT® Editorial Panel approval of Category III CPT® code on May 30, 2025, effective January 1, 2026 (note: a Category III CPT® code is a temporary emerging-technology tracking and data-collection code with no established payment); (c) ISO 13485:2016 Quality Management System Certification issued June 25, 2026 by BSI Notified Body (Certificate No. MD 842733).
[4] Prior Technology Investment ($20M+), 8 Issued Patent Families & U.S. Clinical Studies: SEC Form C-AR (July 8, 2026), pp. 5–6, 8–9, 14 & Note 7 (pp. 50–51): Exclusive worldwide license from the University of British Columbia (UBC) and British Columbia Cancer Agency (BCCA) covering 20+ years of development and 8 issued patent families for AURA™ and CORE™; in addition to Vita Imaging’s investment of over $5 million, approximately US$15 million was expended to advance the technology by the BCCA Research Centre and a predecessor company; U.S. clinical studies including US-01 (100 subjects), U.S. VA Tampa & Boston Hospital study (250+ subjects), MRMC study (30+ dermatologists), and a 50-subject precision study at a dermatology clinic in Arizona.
[5] U.S. Skin Cancer Prevalence, Survival & Treatment Cost ($8.1B–$8.9B): SEC Form C-AR (July 8, 2026), p. 8, citing the American Academy of Dermatology (aad.org/media/stats-skin-cancer) and CDC: 1 in 5 Americans develop skin cancer; 5.0M to 6.1M treated annually at $8.1B ($4.8B NMSC + $3.3B melanoma) to $8.9B annual U.S. cost; 99% five-year survival rate when melanoma is detected early; WHO / WCRF report of 132,000+ global melanoma diagnoses annually.
[6] Global Market Growth ($9B to $33B), NMSC Surge (+284%) & Visual Inspection Study: Investor Presentation (2026), Slides 2 & 3, citing Skin Cancer Diagnostics Market (RM) ($9B market in 2025 projected to surpass $33B by 2033 at 8.4% CAGR; 200% surge in urgent UK referrals), International Agency for Research on Cancer (IARC) (global NMSC rose 284% from 1.66M to 6.34M cases), and University of Birmingham Study (2018).
[7] Multi-Stream Business Model: Investor Presentation (2026), Slides 8, 9 & 11 (AURA™ console capital sales or 60/40 revenue-sharing physician lease; single-use disposable calibration/hygiene probe tips; annual maintenance service contracts; anonymized spectral imaging database under clinic data-sharing agreements).
[8] Target International Markets (KSA, UAE, EU & UK): SEC Form C-AR (July 8, 2026), p. 9 (ISO 13485 certification supporting EU CE Mark, UK MHRA registration, and regulatory registration in UAE & KSA; mandated insurance coverage for skin cancer diagnostics in KSA); Investor Presentation (2026), Slide 4, citing Journal of Pioneering Medical Sciences (2024; KSA market projected to reach $133.6M by 2033) and PLOS One (Jan 2025; UAE market projected to reach $88.2M by 2033).
[9] Executive Track Record & Founder Financing ($2.4M+): SEC Form C-AR (July 8, 2026), pp. 10–11, 18, 20, 24: CEO & Chairman Thinh Tran founded Sigma Designs (NASDAQ: SIGM) in 1982 ($2B peak market cap over 36 years as CEO & Chairman) and has personally advanced $2,405,589 to Vita Imaging under his 3% convertible line of credit as of May 31, 2026. Forward-looking regulatory clearances, commercialization plans, and market projections are estimates and are not guaranteed.